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The recent develo~aent of a high performance liquid chromatography 
assay method for the analysis of penicillamine in biological 
samples such as plasma, whole blood, and urine has provided a 
specific and sensitive assay method to aid in the study of 
penicillamine pharmacokinetics. Several investigators have reported 
measuring the plasma conoentratlon of penicillemine. Some of these 
investigators have indicated that the plasma must be assayed 
immediately. However, such restrictions can limit the feasibility 
of a pharmacokinetlc study. The results of this paper demonstrate 
the instabillty of penlcillsmine in plasma, albumin solutions, and 
whole blood. The rate of loss of penicillemine was shown to be 
influenced by the concentration of albumin. As a result of the 
significant loss of penioillemine over a short p~riod of time, 
plasma or whole blood samples must be deproteina~immediately upon 
collection to avoid the loss of reduced penicill~ine. Methods are 
presented for the preparation of biological s u m p i ~  so that the 
oxidation of penicillamine is prevented and the scruples can be held 
for several days prior to analysis. 
Penicillamine has been used therapeutically since 1954 when it was first 
introduced by Walshe (I) for the treatment of Wilson's disease. Since that time 
a number of other uses for penicillamine have been advocated including the 
treatment of cystlnurla (2), rheumatoid arthritis (3), metal intoxication (4), 
primary billiary cirrhosis (5), chronic hepatitis (6), and hyperbilirubinemia 
(7). Lyle recently has published an excellent review of penicillemine (8). 
A detailed human pharmacokinetic study of penicillamine has not been 
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reported primarily due to the lack of a specific and sensitive assay for 
penicillamine in biological fluids. Some investigators have reported 
pharmacokinetic studies of penicillamine using radiolabeled drug (9-14). 
However these studies are inappropriate as the radioactivity represents both 
metabolized and unchanged drug. Analytical methods for the analysis of 
penicillamine such as colorimetric (15,16), gas chromatographic (17), immuno- 
logical (18,19) and amino acid analyzer (20) have been developed. These methods 
have limitations such as non-speciflclty, low sensitivity, or require complex 
manipulations of the samples which renders their application in the analysis of 
pharmacokinetic samples inappropriate. The recent development of a high per- 
formance liquid chromatography (HPLC) method by Saetre and Rabenstein (21) for 
the analysis of penicillamine using an electrochemical detector has provided a 
simple, specific and sensitive analytical tool suitable for pharmacokinetic 
samples. We have used this HPLC method in our laboratory with some modifi- 
cations to assess the stability of the reduced form of penicillamine in plasma, 
albumin solutions, and whole blood. The results of these studies and the 
corresponding implications for proposed pharmacokinetic studies are presented. 
Methods 
The stability of penicillamine in plasma, whole blood, and buffered albumin 
solutions was studied in vitro using plasma obtained from the American National 
Red Cross Blood Service (single donor source, citrate-phosphate anticoagulant 
used), whole blood obtained from a normal volunteer (ethylene diamine tetracetic 
acid disodium (EDTA) anticoagulant used) and normal human serum albumin 25% 
obtained from the American National Red Cross Blood Service. 
The various concentrations of albumin solutions studied were prepared by 
diluting the normal human serum albumin 25% to the appropriate concentration 
using an isotonic pH:7.4 imidazole buffer (imidazole 4.3 g., HCI 0.1M. 225 ml., 
EDTA 250 mg., deionized water q.s. to 250 ml.). 
All of the experiments were conducted at controlled temperatures. An alli- 
quot of a biological fluid (25 ml.) was pipetted into a water jacketed flask. 
The flask was maintained at a constant temperature (10, 25, 37, or 55°C.) by 
circulating controlled temperature water through the water jacket from a Brink- 
mann MGW Lauda refrigerated water bath (model RC-3) equipped with a MGW Lauda 
(model T-2) temperature controller (Brinkmann Instruments, Inc. Westbury, 
N.Y. 11590). The temperature of the biological medium was allowed sufficient 
time to equilibrate to the controlled temperature before the addition of peni- 
cillamine. The biological medium was constantly stirred using a teflon coated 
magnetic stirring bar. 
The experiments were started by the addition of a concentrated solution of 
D-penicillamine (Aldrich Chemical Co., Milwaukee, Wisconsin 53233) to the flask. 
At timed intervals following the addition, samples were withdrawn from the 
flask. For the initial rate studies, samples (1.O ml.) were obtained at .25, 
I, 2, 3, 4, 5, 7, 9, and 11 minutes after the penicillamlne addition. For the 
other studies, samples (2.0 ml.) were obtained at I, 10, 20, 30, 40, 50, 60, 707 
80, and 90 minutes after addition of the concentrated penicillamine solution. 
The samples were treated immediately to cause a precipitation of the 
proteins and a decrease in pH. The plasma samples were added to test tubes 
containing a trichloroacetlc acid solution (15% w/v) (0.25 ml. per ml. of 
sample). The albumin samples were added to test tubes containing a metaphos- 
phoric acid solution (500 g./L.) (0.25 ml. per ml. of sample). The whole blood 
samples were added to test tubes containing an EDTA solution (200 mg./L.) (an 
equal volume to that of the sample) and the blood hemolyzed. Immediately an 
alliquot of a metaphosphorio acid solution (500 g./L.) (0.5 ml. per ml. of 
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original sample) was added to the hemolyzed blood sample to precipitate the 
proteins. All of the precipitated samples were agitated to ensure complete 
precipitation and mixing. The initial rate samples were centrifuged at 15000 
rpm (Eppendorf Micro Centrifuge model 5412, Brinkmann Instruments, Inc. West- 
bury, N.Y. 11590) for one minute. The supernatant fluids of these samples were 
decanted into clean test tubes and injected directly onto the HPLC. All of the 
other samples were centrifuged at 2500 rpm (Sorvall model RC-3 refrigerated 
centrifuge, Dupont Instruments, Newtown, Ct. 06470) for 6 minutes. The resul- 
ting protein free supernatant fluids were decanted and then filtered through a 
0.45 ~. membrane filter (13 mm. Swlnnex with HATF01300 membrane filter, Milli- 
pore Corporation, Bedford, Mass, 01730) into clean test tubes. The concen- 
tration of penicillamine remained unchanged in the protein free supernatant of 
samples that were treated by the above methods. For penicillamine analysis 
20 WI. alliquots of the samples were injected onto the HPLC system. 
For the plasma and 5% albumin solutions studied at the three different 
temperatures (10, 25, and 37°C.) the theoretical initial concentration after the 
addition of the concentrated penicillsmine solution was 19.6 ~g./ml. The theo- 
retical initial concentration was 38.3 ~g./ml. for the whole blood study and was 
19.5 ~g./ml. in the 1, 3, 5, 7% albumin study. Initial rate studies were 
completed using initial concentrations of approximately 6, 23, and 200 ~g./ml. 
penicillamine for the 5% buffered albumin solutions only. 
The HPLC method and electrochemical detector utilized for these studies are 
a modification of the HPLC method and detector reported previously by Saetre and 
Rabenstein (21). Two stainless steel columns packed with Zipax SCX (Dupont 
Instruments, Wilmington, Del 19898) (0.41 x 5 cm. and 0.41 x 30 cm.) were used 
as the guard and analytical columns. A citrate/phosphate buffer (citric acid 
0.03 M., and sodium dibasic phosphate 0.01M.) was used as the mobile phase. 
The flow rate was maintained at 2.6 ml./mln, and resulted in a back pressure of 
300-400 psi. A mercury gold amalgam working electrode, Ag/AgCI reference elec- 
trode, and a glassy carbon auxiliary electrode were used in the electrochemical 
detector's transducer (model TL-6A Bioanalytical Systems, Inc. West Lafayette, 
Indiana 47906). The LC-4 amperometric controller (Bioanalytical Systems, Inc., 
West Lafayette, Indiana 47906) was used to maintain the potential of the working 
electrode at +0.01 V. vs. the Ag/AgCI reference electrode. Full details of the 
HPLC system will be published elsewhere. 
The electrolysis method for the determination of total penicillamine 
content utilized the electrolysis cell described by Saetre and Rabenstein (21). 
A Wenking potentiostat (model 61RS Brinkmann Instruments, Inc. Westbury, N.Y., 
11590) with an external 270 ohm resister between the working and reference 
electrodes was used as a galvanostat to supply 6.4 mA of current to the electro- 
lysis cell for the reduction of penicillamine disulfides to penicillamine. A 
citric acid solution (0.4 M.) was used to dilute the samples for the electro- 
lysis procedure (equal volume used to that of the sample electrolyzed). 
Results 
The in vitro concentrations of penicillamine in plasma or albumin solutions 
have been shown to rapidly decrease with time. At the concentrations used, the 
rate of this loss was shown to be temperature dependent. Figure I shows the 
loss of penicillsmine at three temperatures that occurred when penicillsmine was 
added to normal human plasma in vitro. Figure 2 shows the loss of penicillamine 
in a 5% albumin solution at the same three temperatures. (All figures were 
computer drawn. The axis numerals do not represent the data accuracy). 
The observed loss of penicillamine in these experiments is not due to the 
experimental conditions. The results of simultaneous control experiments using 
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FIG. 1 
The Loss of Penicillamine in Normal 
Human Plasma. squares=10°C., 
clrcles=25°C., trlangles=37°C. 
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FIG. 2 
The Loss of Penlcillamlne in a 







The Loss of Penicillamine in a 
52 Albumin Solution at 250C. 
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the same experiments/ conditions are shown in Table I. The control experiment 
results demonstrate that the loss of penicillamine is not due to a pH phenomenon 
alone. Aqueous solutions of penlcillemine are reported to be stable in the pH 
range from 2-4 and thus a loss of peniciilemine may be expected at physio- 
logical pH (pH=7.~). However, in the period of time considered in our experi- 
ments no penioillemine loss was observed at pH 7.~. 
TABLE I 
Stability of Penicillemine I in the Solutions Used 
to Dilute the 25~ Normal Human Serum Albumin 
EDTA 2 Solution Imidazole 3 Buffer 











































1 ) A concentrated penicillamine solution was added to the test 
solution at time zero to produce an approximate initial 
penicillamine concentration of 19.0 ~g./ml. 
2) Ethylene diamine tetracetic acid disodlum salt solution. 
Previous investigators (see reference 21 ) have also demonstrated 
the stability of penicillemlne in EDTA solutions. The 
temperature was at ambient temperature (approximately 25°C. ). 
3) The imidazole buffer contained ~.3 g. imidazole, 250 mg. EDTA, 
225 -I. HCI, q.s. to 250 ml. with deionized water. The 
temperature was controlled at 25°C. 
The rate of loss was shown to be dependent on the concentration of albumin. 
Figure 3 shows the loss of penicillemlne that occurred when penicillemine was 
added to a I, 3, 5, or 7~ solution of albumin. 
The loss of penicillemine may be due to more than one reaction. The 
results of the study of penicillamine in a 5~ albumin solution and in antico- 
agulated ~hole blood are shown in Figures 4 and 5. Not all of the original 
amount of penicillemine could be regenerated using the electrolysis reductive 
procedure described in the methods. These results indicate that perhaps more 
than one product is being formed from the loss of penicillemine, a product that 
can he regenerated (ie. disulfides) end a product that cannot. 
Figures 6, 7, and 8 show the log linear results of the initial rate studies 
of the loss of penicillamine in a 5~ solution of albumin at three different 
initial concentrations and at four temperatures. The two lower concentrations 
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FIG. 5 
The Loss of Penicillamine in EDTA 
Anticoagulated Whole Blood at 25°C. 
squares = reduced penlcillamine 
circles = total penicillamine 
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The Initial Loss of Penicillamine in 
a 5% Albumin Solution. (initial 
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FIG. 8 
The Initial Loss of Penicillamine in 
a 5% Albumin Solution. (initial 
concentration of 200. ~g./ml.) 
circles=25°C., triangles=37°C., 
stars=55°C. 
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of penicillamine showed a temperature dependency of the rates and the Arrhenius 
plots for these data are shown in Figure 9. However, the highest concentration 
of penicillamine (200 ug./ml.) represents a 10 fold excess in penicillamine and 
the data are not temperature dependent. A summary of the observed rate 
constants for these experiments is given in Table II. The activation energies 
for the 6 and 23 ug./ml, initial concentration experiments were 3.81 and 3.00 
Kcal./mole respectively. 
TABLE II 
Initial Rates of Penicillamine Loss in a 5% Albumin Solution I 
Kobs (minutes -I ) 
Temp@rature .............................................................. 
°C. Penicillamine Initial Concentratlon 2 
6 ~g./ml. 23 wg./ml. 200 ~g./ml. 
10 0.0325 0.0326 
25 0.0602 0.0570 0.121 
37 0.0933 0.0796 0.158 
55 0.209 0.142 0.119 
I) A 5% albumin solution corresponding to a 7.5 x 10 M. solution 
(molecular weight of albumin 66500 g./mole, see reference 22). 
2) The approximate initial concentrations of penicil~amlne (6, 23, and 2~0 
~g./ml.) correspond to 4.02 x 10- M., 1.54 x 10 -7 M., and 1.34 x 10 -~ 
M. 
13.00 3.15 3.30 3.45 3.60 
1/T x 103 
FIG. 9 
Arrhenius Plots for Penicillamine Loss in a 5% Albumin Solution. 
circles= 6 ~g./ml. squares= 23 ~g./ml. initial concentrations. 
196 Penicillamlne in Biological Samples Vol. 27, No. 3, 1980 
The lack of a temperature dependency at the highest concentration studied 
indicates that the reaction meehaniem may be occurring at a "specific site" on 
the albumin molecule. Due to the 10 fold excess of penicillemine this "specific 
site" would always be occupied and thus the reaction would proceed at a constant 
rate independent of the temperature. Studies of albumin (22) have indicated 
that there is only one free sulfhydryl group in the whole molecule of albumin 
resulting from a eysteine residual. This or some other "specific site" may be 
responsible for the loss of penicillamine observed. 
The loss of penicillamlne in biological samples such as plasma and whole 
blood presents a major obstacle for the successful completion of a phammaco- 
kinetic study of this drug. It is essential that the analytical method used to 
quantify the concentration of a drug measures the actual concentration of the 
sample as it was obtained from the subject or animal of study. The rapid 
disappearance of penieillamine in biological media demonstrated by the results 
of this paper eonfiPm the necessity of actiug quickly to stabilize the penicill- 
amine present in a biological sample. 
Previous investigators have also suggested the problem of penlcillamine 
loss. Russell et al. (23) stated that plasma samples must be assayed as soon as 
they are obtained. This approach, however, limits the feasibility of most 
pharmaeokinetic studies. Mann and Mitchell (24) stressed the necessity of using 
EDTA as an anticoagulant. However, the results shown in Figure 5 confiPm that 
penieillamine is lost even in blood where EDTA was used as the anticoagulant. 
TABLE III 
Stability of Penicillamine I in a Protein Free Supernatant 
of Hemolyzed Whole Blood and an EDTA Solution. 
Whole Blood Supernatant 2 EDTA Solution 3 
Time ~ ......................................................................... 
days ~ Penicillamine (Percent of Penlcillamine (Percen t of 
I Cone. ug./ml. Initial) Cone. Ug./ml. Initial) 
. . . . . . .  + . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Z 
Initial ~ 2.17 6.30 10.4 2.00 5.96 10.7 
I ~1.90 (87.6) 6.22 (98.7) 9.84 (94.6) 1.95 (97.5) 5.77 (96.8) 10.2 (95.3) 
2 ~1.74 (80.2) 5.76 (91.4) 9.64 (92.7) 1.94 (97.0) 5.84 (98.0) 10.6 (99.0) 
8 11.81 (83.4) 5.31 (84.3) 9.33 (89.7) 1.93 (96.5) 5.76 (96.6) 10.5 (98.1) 
I ) A concentrated solution of penieillamine was added to the whole blood 
supernatant or the control EDTA solutions to produce an approximate 
initial concentration of I. 97, 5.80 or 9.87 ~g./ml. Samples were 
refrigerated at 4°C. 
2) A protein free hemolyzed whole blood supernatant was produced by the 
addition of 2.0 ml. of whole blood to 2.0 ml of EDTA solution (I g./ 
L.) followed by the addition of 1.0 ml. of metaphosphoric acid solution 
(500 g./L. ). After mixing and centrifuEaticn the supernatant ~as 
decanted and filtered through a membrane filter (0.45 P. ). 
3) The EDTA solution (I E./L.) was used as a control for this experiment. 
Previous investigators have shown the excellent stability of reduced 
penlcillamne in EDTA solutions (see reference 21). 
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As demonstrated by the results presented in this paper, the protein content 
particularly the albumin of the samples plays a key role in the loss of peni- 
cillamine. If blood or plasma samples are treated immediately to precipitate 
the proteins and lower the pH the loss of penicillamine will be minimized. 
Tables III and IV show the results of a study of the stability of penicill- 
amine in the protein free supernatant obtained from whole blood. The loss of 
penicillamlne was minimal in these studies over a period of 6-8 days. Recovery 
studies of penicillamine added to whole blood was 88.2, 93.7, 85.7, and 87.7 
percent. 
TABLE IV 
Stability of Penicillamine I in a Protein Free Supernatant of 
Hemolyzed Whole Blood Solution and an EDTA Solution 
Whole Blood 2 I EDTA 
Supernatant I Solution 3 
Time + ............................ 
days Penicillamine Percent oflPenicillsmine Percent of 
IConc. ~./ml. TheoreticallConc. ~g./ml. Theoretical 














92.9 98.41 4.75 15.0 
95.2 98.41 5.03 15.3 
101. 101. I 4.93 15.3 
96.5 99.71 4.74 15.0 
89.5 93.61 5.00 15.0 







I) A concentrated penicillamine solution was added to the 
supernatant or control solution to produce an initial 
concentration of 5.00 ~g./ml and 15.0 ~g./ml. The 
samples were refrigerated at 4°C. 
2) The protein free hemolyzed blood supernatant was 
produced by adding 2.0 ml. of whole blood to 7.0 ml. of 
EDTA (200 mE./L.) solution. After 1 minute 1.0 ml. of 
metaphosphoric acid (500 g./L.) solution was added. 
After 5 minutes the sample was centrifuged for 10 
minutes at 2500 rpm. The supernatant was decanted and 
filtered through a membrane filter (0.45 W.). 
3) An EDTA (1 g./L.) solution was used as a control. 
Penicillamlne has excellent stability in EDTA solutions 
(see reference 21). 
The studies reported here are for the in vitro initial rate of loss of 
penicillamlne. However, loss of penicillamine by similar reactions probably 
also occurs invivo. Our results indicate that the rate of reaction is reduced 
with time. Thus the impact on pharmacokinetic samples collected minutes to 
hours after the dose of penicillamine probably will be less that the initial 
rate of loss demonstrated by our results. Nevertheless, it is important that 
all samples be deproteinated as soon an possible alter they are collected from 
the subject or animal being studied. The whole blood treatment procedure used 
in the above studies can generally be completed in less that two minutes. 
In ~itro distribution studies of penicillamine in whole blood indicate that 
most of the penicillamlne is found in the extracellular plasma compartment. 
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Thus when the cell lysis occurs in the whole blood procedure, a "dilution" of 
the sample results beyond that caused by the addition of the EDTA diluent alone. 
In addition, the procedure for the treatment of whole blood samples results in a 
greater dilution of the actual analytical samples than is necessary to process 
an equivalent plasma sample (see methods). These factors coupled together mean 
that the analytical sample resulting from the whole blood procedure is less 
conoentrated than the analytical sample obtained from plasma of the same blood 
sample. Thus as the limit of sensitivity of the analytical assay is approached, 
plasma samples can be assayed for a longer period of time because of their 
relative higher concentration. Due to this advantage, plasma samples may be 
more appropriate for pharmacokinetic studies of penicillamine. 
To prevent the excessive loss of penicillamine, however, the plasma must be 
separated from the whole blood and deproteinated as quickly as possible. For 
this purpose we employ a micro centrifuge (15000 rpm - 30 sec.) to separate 
heparlnized whole blood samples into plasma and packed cells. The plasma is 
then treated as described in the methods above. A recovery study of 
penicillamine added to normal plasma yielded from 103 to 109 percent. Using 
this methodology the blood samples can generally be processed (plasma separated 
and proteins precipitated) in less than two minutes. 
This research was supported in part by a National Institutes of Health 
Grant (AM-20557-02-$I). 
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